Health ❯ Obesity ❯ Weight Loss

Medications

GLP-1 Receptor Agonists GLP-1 Drugs Semaglutide Mounjaro GLP-1 Agonists Wegovy Ozempic GLP-1 Tirzepatide Zepbound NHS Clinical Trials Long-term Effects Diabetes Treatment Semaglutide and Tirzepatide NHS Services Long-term Treatment Hormonal Treatments Drug Efficacy Wegovy and Mounjaro Ozempic and Wegovy Medicare and Medicaid Coverage Generic Drugs Semaglutides Long-term Use Novo Nordisk GLP-1RA Benefits Side Effects Eli Lilly GLP-1 Treatments GLP-1s Prescription Services GLP-1 Therapies Weight Loss Medicines GLP-1 Injections Wegovy and Ozempic GLP-1 Medications Subsidization Copycat Drugs Orforglipron Public Opinion Mounjaro and Wegovy

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

UBT251 targets GLP‑1, GIP plus glucagon for a mechanistically distinct approach to weight management.

Weight Returns Quickly After Stopping GLP-1 Drugs, Oxford Review Finds

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

GLP-1 Drugs Linked to Lower Five-Year Death Risk in Colon Cancer, UCSD Study Finds

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

Pilot Study Ties GLP-1 Drugs to Slower Alcohol Absorption and Milder Intoxication

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

GLP-1 Weight-Loss Drugs Linked to Testosterone Normalization in Men

GLP-1 Drugs Linked to Lower Cancer Risk and Mortality in New Study